Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-19
DOI
10.1038/s41467-021-26239-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mapping and role of T cell response in SARS-CoV-2–infected mice
- (2021) Zhen Zhuang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
- (2021) Gustavo Garcia et al. Cell Reports
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment
- (2020) Jing Sun et al. CELL
- Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
- (2020) Robert L. Hoffman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
- (2020) Raveen Rathnasinghe et al. Emerging Microbes & Infections
- Development of an efficient enzyme production and structure-based discovery platform for BACE1 inhibitors
- (2019) Yu-Chen Yen et al. BIOCHEMISTRY
- Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection
- (2017) Yoshiki Koizumi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
- (2016) Thanigaimalai Pillaiyar et al. JOURNAL OF MEDICINAL CHEMISTRY
- X-Ray Structure and Inhibition of 3C-like Protease from Porcine Epidemic Diarrhea Virus
- (2016) Sarah E. St. John et al. Scientific Reports
- Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4—The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS)
- (2015) Sarah E. St. John et al. BIOORGANIC & MEDICINAL CHEMISTRY
- X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design
- (2015) Sarah E. St. John et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro)
- (2015) Sakshi Tomar et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Charting the human proteome: Understanding disease using a tissue-based atlas
- (2015) M. Uhlen et al. SCIENCE
- Coronaviruses Resistant to a 3C-Like Protease Inhibitor Are Attenuated for Replication and Pathogenesis, Revealing a Low Genetic Barrier but High Fitness Cost of Resistance
- (2014) X. Deng et al. JOURNAL OF VIROLOGY
- A Mouse Model for Betacoronavirus Subgroup 2c Using a Bat Coronavirus Strain HKU5 Variant
- (2014) S. Agnihothram et al. mBio
- Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors
- (2012) Micaela B. Reddy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Temperature-Sensitive Mutants and Revertants in the Coronavirus Nonstructural Protein 5 Protease (3CLpro) Define Residues Involved in Long-Distance Communication and Regulation of Protease Activity
- (2012) C. C. Stobart et al. JOURNAL OF VIROLOGY
- pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery
- (2012) Manthena V. Varma et al. MOLECULAR PHARMACEUTICS
- Ad5:Ad48 Hexon Hypervariable Region Substitutions Lead to Toxicity and Increased Inflammatory Responses Following Intravenous Delivery
- (2012) Lynda Coughlan et al. MOLECULAR THERAPY
- Development of a new permeability assay using low‐efflux MDCKII cells
- (2011) Li Di et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease
- (2011) M. Frieman et al. JOURNAL OF VIROLOGY
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a “chemical knock-out equivalent” to assess the impact of efflux transporters on oral drug absorption in the rat
- (2009) Amit S. Kalgutkar et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- In Vivo Retargeting of Adenovirus Type 5 to v 6 Integrin Results in Reduced Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery
- (2009) L. Coughlan et al. JOURNAL OF VIROLOGY
- Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
- (2008) Lin Shen et al. NATURE MEDICINE
- Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery
- (2007) Valerie Grum-Tokars et al. VIRUS RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More